Skip to main contentSkip to navigation
Sirius Investors
Item 9 Labs Corp.

Item 9 Labs Corp.

INLB
OTCHealthcare

Item 9 Labs Corp. (INLB) Investment Research Dashboard

About Item 9 Labs Corp. (INLB) stock analysis

Get live INLB stock price $0.00, comprehensive Item 9 Labs Corp. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time INLB stock data and investment insights.

0.00
0.00%Today
Market Cap
70.18K
Volume
20.00K
52W High
0.00
52W Low
0.00

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Based in the United States, Item 9 Labs Corp. operates as a comprehensive cannabis company, encompassing both vertical integration in cannabis operations and the franchising of dispensaries. The firm produces a wide spectrum of cannabis and related g...

Company Information

CEO
Jeffrey I. Rassas
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
97

Contact Information

Address
2727 North 3rd Street
Country
US

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - Specialty & Generic

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.15) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Item 9 Labs Corp. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Item 9 Labs Corp.
  • Investors should consider how Item 9 Labs Corp. fits within their overall portfolio allocation

Market Cap

70.18K

Beta

0.15

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

73/100 ⭐⭐⭐⭐⭐

Overall
+0.6%
NYSE
+0.7%
NASDAQ
+0.4%
Sector1D1W1MP/EScore
Financial Services+1.9%+2.8%+4.0%19.2
98/100⭐⭐⭐⭐⭐
Communication Services+1.5%-0.5%+3.1%22.3
74/100⭐⭐⭐⭐⭐
Healthcare+0.6%+1.2%+1.5%24.0
73/100⭐⭐⭐⭐⭐
Basic Materials+0.9%+1.7%+0.2%25.3
66/100⭐⭐⭐⭐
Consumer Defensive-0.0%+2.0%+0.9%29.8
63/100⭐⭐⭐⭐
Real Estate+0.4%+0.9%-1.6%29.5
50/100⭐⭐⭐
Energy-1.7%-3.3%-3.7%19.2
39/100⭐⭐
Utilities-1.1%-0.0%-4.5%26.8
35/100⭐⭐
Industrials+0.7%+0.5%-9.8%30.0
21/100
Technology+0.9%-1.3%-6.9%40.9
18/100
Consumer Cyclical+0.3%-1.7%-6.0%42.8
14/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.